Postpartum hemorrhage is defined as blood loss of ≥500 mL for vaginal delivery after completion of the 3rd stage of labor while for cesarean delivery, the cut-off is 1000 mL.
It may present as either early (primary) or late (secondary) postpartum hemorrhage.
Postpartum hemorrhage may produce hemodynamic instability during the 1st 24 hours after delivery.
Immediate administration of the antifibrinolytic tranexamic acid increased the likelihood of survival in patients with acute severe haemorrhage, with efficacy reducing with every 15-minute delay in treatment, according to a large study.
Women given tranexamic acid within three hours of giving birth appear to have a reduced risk of death due to postpartum haemorrhage (PPH), according to findings of the large, multinational WOMAN* trial.
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
TX-001HR, a fixed-dose combination of oestradiol and progesterone, yields clinically meaningful improvements in the frequency and/or severity vasomotor symptoms in menopausal women with a uterus, according to a study.
Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.